PT  - JOURNAL ARTICLE
AU  - Killian Nugent
AU  - James Good
TI  - The oligometastatic paradigm and the role of radiotherapy
AID  - 10.7861/clinmed.2022-0559
DP  - 2023 Jan 01
TA  - Clinical Medicine
PG  - 61--64
VI  - 23
IP  - 1
4099  - http://www.rcpjournals.org/content/23/1/61.short
4100  - http://www.rcpjournals.org/content/23/1/61.full
SO  - Clin Med2023 Jan 01; 23
AB  - Most cancer-related deaths are due to metastatic disease. There is now an emerging evidence base suggesting that a subgroup of metastatic patients benefit significantly from local resection (surgery) or ablation (stereotactic ablative body radiation, SABR) of their metastatic sites. These patients are in what has been termed the ‘oligometastatic state’, a transitional window between local and disseminated disease where locally ablative, metastasis-directed therapy prolongs progression-free survival, improves overall survival and sometimes achieves cure. Appropriately selecting those who fit this oligometastatic phenotype, while integrating advances in ablative technologies such as SABR with modern systemic treatments, is an evolving challenge for oncologists.